US equities |
MU $1,028.79 ▼-1.60% NVDA $238.06 ▼-0.49% AMD $641.63 ▼-1.20% INTC $113.41 ▲+0.81% SPCX $168.34 ▼-2.08% SNDK $1,657.74 ▼-0.16% TSLA $377.69 ▼-0.79% AAPL $335.07 ▲+0.43%
FinancialContent

NanoViricides, Inc. Common Stock (NY:NNVC)

1.468 +0.068 (+4.84%)
Delayed Quote Updated: 9:51 AM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NanoViricides, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
From NanoViricides
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Advances NV-387 Toward Phase II Trial for Bundibugyo Ebola in DRC
Via Investor Brand Network
Topics Death Intellectual Property
News headline image
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
From NanoViricides
Via ACCESS Newswire
News headline image
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
From NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Ships NV-387 Drug Supply to DRC for Phase II MPox Trial
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
From NanoViricides
Via ACCESS Newswire
NetworkNewsBreaks – NanoViricides (NYSE American: NNVC) Receives DRC Approval to Advance Proposed Phase II Ebola Trial
Via Investor Brand Network
Topics Intellectual Property
News headline image
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
Via ACCESS Newswire
News headline image
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies
Via ACCESS Newswire
MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Candidate for Bundibugyo Ebola Outbreak
Via Investor Brand Network
Topics Intellectual Property
News headline image
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Closes $2 Million Registered Direct Offering
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Candidate Amid Ebola Outbreak
Via Investor Brand Network
Topics Intellectual Property
News headline image
Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances NV-387 Development Across Multiple Viral Disease Targets
Via Investor Brand Network
Topics Intellectual Property
MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Prices $2 Million Registered Direct Offering
Via Investor Brand Network
News headline image
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
Via ACCESS Newswire
News headline image
NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II
Via ACCESS Newswire
BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Candidate Following Andes Hantavirus Incident
Via Investor Brand Network
News headline image
Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Participate in D. Boral Capital Global Conference
Via Investor Brand Network
MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Receives Orphan Drug Designation for NV-387
Via Investor Brand Network
News headline image
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Measles Treatment
Via Investor Brand Network
News headline image
Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Files for Rare Pediatric Disease Designation for Measles Drug Candidate
Via Investor Brand Network
News headline image
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Initiate Phase II MPox Trial in DRC
Via Investor Brand Network
Topics Intellectual Property
News headline image
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >